The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

Stanley McGreal, Ciara Hughes, Margaret Murray, OP Friery, LH Patterson, DG Hirst, SR McKeown

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. The aim of this study was to examine the ability of AQ4N to potentiate the anti-tumour effect of cisplatin and to compare it to the chemopotentiation effect of tirapazamine. In the T50/80 murine tumour model, AQ4N (50-100 mg/kg) was administered 30 min, 2.5 or 6 h prior to cisplatin (4 mg/kg or 8 mg/kg); this produced an anti-tumour effect that was approximately 1.5 to 2 times greater than that achieved by a single 4 or 8 mg/kg dose of cisplatin. Tirapazamine (25 mg/kg) administered 2.5 h prior to cisplatin (4 mg/kg) resulted in a small increase in anti-tumour efficacy. AQ4N was also successful in enhancing the anti-tumour effect of cisplatin in the SCCVII and RIF-1 murine tumour models. This resulted in an increased cell kill of greater than 3 logs in both models; this was a greater cell kill than that observed for tirapazamine with cisplatin. Combination of cisplatin with AQ4N or tirapazamine resulted in no additional bone marrow toxicity compared to cisplatin administered alone. In conclusion, AQ4N has the potential to improve the clinical efficacy of cisplatin. (C) 2001 Cancer Research Campaign http://www.bjeancer.com.
LanguageEnglish
Pages625-629
JournalBRITISH JOURNAL OF CANCER
Volume85
Issue number4
DOIs
Publication statusPublished - Aug 2001

Fingerprint

tirapazamine
Cisplatin
Pharmaceutical Preparations
Neoplasms
AQ4N
Radiation Effects
Cyclophosphamide
Bone Marrow
Research

Keywords

  • AQ4N+cisplatin
  • chemopotentiation

Cite this

McGreal, Stanley ; Hughes, Ciara ; Murray, Margaret ; Friery, OP ; Patterson, LH ; Hirst, DG ; McKeown, SR. / The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. In: BRITISH JOURNAL OF CANCER. 2001 ; Vol. 85, No. 4. pp. 625-629.
@article{cf55e8aedca9431ea3ef14e4c70d6618,
title = "The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N",
abstract = "AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. The aim of this study was to examine the ability of AQ4N to potentiate the anti-tumour effect of cisplatin and to compare it to the chemopotentiation effect of tirapazamine. In the T50/80 murine tumour model, AQ4N (50-100 mg/kg) was administered 30 min, 2.5 or 6 h prior to cisplatin (4 mg/kg or 8 mg/kg); this produced an anti-tumour effect that was approximately 1.5 to 2 times greater than that achieved by a single 4 or 8 mg/kg dose of cisplatin. Tirapazamine (25 mg/kg) administered 2.5 h prior to cisplatin (4 mg/kg) resulted in a small increase in anti-tumour efficacy. AQ4N was also successful in enhancing the anti-tumour effect of cisplatin in the SCCVII and RIF-1 murine tumour models. This resulted in an increased cell kill of greater than 3 logs in both models; this was a greater cell kill than that observed for tirapazamine with cisplatin. Combination of cisplatin with AQ4N or tirapazamine resulted in no additional bone marrow toxicity compared to cisplatin administered alone. In conclusion, AQ4N has the potential to improve the clinical efficacy of cisplatin. (C) 2001 Cancer Research Campaign http://www.bjeancer.com.",
keywords = "AQ4N+cisplatin, chemopotentiation",
author = "Stanley McGreal and Ciara Hughes and Margaret Murray and OP Friery and LH Patterson and DG Hirst and SR McKeown",
year = "2001",
month = "8",
doi = "10.1054/bjoc.2001.1975",
language = "English",
volume = "85",
pages = "625--629",
journal = "BRITISH JOURNAL OF CANCER",
issn = "0007-0920",
number = "4",

}

McGreal, S, Hughes, C, Murray, M, Friery, OP, Patterson, LH, Hirst, DG & McKeown, SR 2001, 'The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N', BRITISH JOURNAL OF CANCER, vol. 85, no. 4, pp. 625-629. https://doi.org/10.1054/bjoc.2001.1975

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. / McGreal, Stanley; Hughes, Ciara; Murray, Margaret; Friery, OP; Patterson, LH; Hirst, DG; McKeown, SR.

In: BRITISH JOURNAL OF CANCER, Vol. 85, No. 4, 08.2001, p. 625-629.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

AU - McGreal, Stanley

AU - Hughes, Ciara

AU - Murray, Margaret

AU - Friery, OP

AU - Patterson, LH

AU - Hirst, DG

AU - McKeown, SR

PY - 2001/8

Y1 - 2001/8

N2 - AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. The aim of this study was to examine the ability of AQ4N to potentiate the anti-tumour effect of cisplatin and to compare it to the chemopotentiation effect of tirapazamine. In the T50/80 murine tumour model, AQ4N (50-100 mg/kg) was administered 30 min, 2.5 or 6 h prior to cisplatin (4 mg/kg or 8 mg/kg); this produced an anti-tumour effect that was approximately 1.5 to 2 times greater than that achieved by a single 4 or 8 mg/kg dose of cisplatin. Tirapazamine (25 mg/kg) administered 2.5 h prior to cisplatin (4 mg/kg) resulted in a small increase in anti-tumour efficacy. AQ4N was also successful in enhancing the anti-tumour effect of cisplatin in the SCCVII and RIF-1 murine tumour models. This resulted in an increased cell kill of greater than 3 logs in both models; this was a greater cell kill than that observed for tirapazamine with cisplatin. Combination of cisplatin with AQ4N or tirapazamine resulted in no additional bone marrow toxicity compared to cisplatin administered alone. In conclusion, AQ4N has the potential to improve the clinical efficacy of cisplatin. (C) 2001 Cancer Research Campaign http://www.bjeancer.com.

AB - AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. The aim of this study was to examine the ability of AQ4N to potentiate the anti-tumour effect of cisplatin and to compare it to the chemopotentiation effect of tirapazamine. In the T50/80 murine tumour model, AQ4N (50-100 mg/kg) was administered 30 min, 2.5 or 6 h prior to cisplatin (4 mg/kg or 8 mg/kg); this produced an anti-tumour effect that was approximately 1.5 to 2 times greater than that achieved by a single 4 or 8 mg/kg dose of cisplatin. Tirapazamine (25 mg/kg) administered 2.5 h prior to cisplatin (4 mg/kg) resulted in a small increase in anti-tumour efficacy. AQ4N was also successful in enhancing the anti-tumour effect of cisplatin in the SCCVII and RIF-1 murine tumour models. This resulted in an increased cell kill of greater than 3 logs in both models; this was a greater cell kill than that observed for tirapazamine with cisplatin. Combination of cisplatin with AQ4N or tirapazamine resulted in no additional bone marrow toxicity compared to cisplatin administered alone. In conclusion, AQ4N has the potential to improve the clinical efficacy of cisplatin. (C) 2001 Cancer Research Campaign http://www.bjeancer.com.

KW - AQ4N+cisplatin

KW - chemopotentiation

U2 - 10.1054/bjoc.2001.1975

DO - 10.1054/bjoc.2001.1975

M3 - Article

VL - 85

SP - 625

EP - 629

JO - BRITISH JOURNAL OF CANCER

T2 - BRITISH JOURNAL OF CANCER

JF - BRITISH JOURNAL OF CANCER

SN - 0007-0920

IS - 4

ER -